# Prognostic Value of Soluble Urokinase Plasminogen Activation Receptor (SUPAR) to Rule Out Complications in Patients Admitted in Emergency Department for Acute Abdominal Pain.

> **NCT05580016** · — · COMPLETED · sponsor: **Poitiers University Hospital** · enrollment: 200 (actual)

## Conditions studied

- Soluble Urokinase Plasminogen Activation Receptor
- Abdominal Pain
- Emergency Department
- Mortality

## Interventions

- **DIAGNOSTIC_TEST:** Soluble Urokinase Plasminogen Activation Receptor measurement

## Key facts

- **NCT ID:** NCT05580016
- **Lead sponsor:** Poitiers University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-09
- **Primary completion:** 2023-11-27
- **Final completion:** 2023-12-27
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2024-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05580016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05580016, "Prognostic Value of Soluble Urokinase Plasminogen Activation Receptor (SUPAR) to Rule Out Complications in Patients Admitted in Emergency Department for Acute Abdominal Pain.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05580016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*